Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma

Pancreatic cancer is one of the leading causes of cancer-related mortality. Diagnosis at an advanced stage, aggressive tumor biology, and chemoresistance all contribute to the overall dismal prognosis. Somatic, non-hereditary activating mutations involving the proto-oncogene Kirsten rat sarcoma viral oncogene (KRAS) are encountered in the vast majority of patients. KRAS mutations are involved in tumor initiation as well as the progression of pancreatic cancer and are key determinants of prognosis. Beyond pancreatic ductal adenocarcinoma (PDAC), KRAS mutations have been reported in multiple human solid-organ neoplasms. Over the past few decades, targeted molecular therapy has evolved into an indispensable part of oncology. Molecules targeting rat sarcoma viral oncogene (RAS) mutations have gained considerable interest in molecular oncology owing to their pivotal role in common cancers such as non-small cell lung, colon, and pancreatic cancer. One of the recent breakthroughs in PDAC treatment is the discovery of the multi-selective RAS inhibitor specific to its ON conformation: the first of its class, the RAS(ON) inhibitor daraxonrasib. Preclinical and early clinical data confirmed its utility in PDAC, leading to United States Food and Drug Administration permission to expand access treatment protocols for patients with previously treated metastatic PDAC in May 2026. This narrative review summarizes the published literature on the safety and efficacy of daraxonrasib in PDAC, based on a comprehensive PubMed literature search. at June 2026, the utility of daraxonrasib is limited to metastatic PDAC as a second-line agent in patients who failed or were intolerant of first-line chemotherapy. An ongoing trial is evaluating the efficacy of daraxonrasib as a first-line targeted therapy in metastatic PDAC. Further, large-scale, blinded, multicenter randomized trials are required to confirm the efficacy and safety of daraxonrasib in PDAC and other solid-organ neoplasms. The orally administered daraxonrasib could be a potential game changer in the treatment of PDAC, which is otherwise considered one of the least chemotherapy-amenable human cancers.

Indexed on Europe PMC as PubMed record 42694779 (DOI 10.7759/cureus.113927). Its title names Daraxonrasib and its text names Pancreatic ductal adenocarcinoma; PubMed types it as a review (review-article, Review). It was matched automatically to the idea "RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable" and no figure has been checked by an editor.